Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 15/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.60 |
| ▸ | CTSL | P07711 | 3/20 | 0.60 |
| ▸ | CTSK | P43235 | 2/20 | 0.60 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CTSH | P09668 | 1/20 | 0.60 |
| ▸ | CTSS | P25774 | 1/20 | 0.60 |
| ▸ | CTSC | P53634 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11067480 | 0.89 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| SCHEMBL11184932 | 0.88 | CAPN1 (0.72) | CAPN1CTSBCTSLCTSKCAPN9 | |
| SCHEMBL11188762 | 0.88 | CAPN1 (0.72) | CAPN1CTSBCTSLCTSKCAPN9 | |
| Agmatine SCHEMBL18784085 | 0.84 | CAPN1 (0.59) | CAPN1CTSBCTSLCTSKCAPN9 | |
| SCHEMBL30643189 | 0.83 | CAPN1 (0.69) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL23132676 | 0.82 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL4740187 | 0.82 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL13283063 | 0.82 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL16452857 | 0.82 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL7087294 | 0.82 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008045017-A2 | SARS AND EBOLA INHIBITORS AND USE THEREOF, AND METHODS FOR THEIR DISCOVERY | DIAMOND SCOTT L (US) | 2008-04-17 | — | — | WO | claimed |
| US-20070203073-A1 | SARS and Ebola inhibitors and use thereof, and methods for their discovery | DIAMOND SCOTT L | 2007-08-30 | — | — | US | claimed |
| US-5560937-A | EXTRACTION WITH AQUEOUS BUFFER CONTAINING PROTEASE INHIBITORS, SEPARATION BY AFFINITY CHROMATOGRAPHY, DESORPTION | SPECTRAL DIAGNOSTICS, INC. (CA) | 1996-10-01 | — | — | US | claimed |
| EP-0641858-A1 | SERUM CALCIUM DEPRESSING FACTOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 1995-03-08 | — | — | EP | claimed |
| JP-55145678-A | — | — | None | — | — | JP | disclosed |
| EP-2690178-B1 | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same | UNIV OKLAHOMA (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10273517-B2 | Methods of producing testosteronan polymers using testosteronan synthase | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170247732-A1 | Methods of Producing Testosteronan Polymers Using Testosteronan Synthase | UNIV OKLAHOMA (US) | 2017-08-31 | — | — | US | disclosed |
| US-9695427-B2 | Methods of producing testosteronan polymers using testosteronan synthase | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160053290-A1 | Production of Defined Monodisperse Heparosan Polymers and Unnatural Polymers with Polysaccharide Synthases | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2016-02-25 | — | — | US | disclosed |
| US-9200024-B2 | Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140154753-A1 | TESTOSTERONAN, A NOVEL HEPAROSAN ANALOG, TESTOSTERONAN SYNTHASE, AND METHODS OF PRODUCTION AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2014-06-05 | — | — | US | disclosed |
| EP-0555479-A1 | EPOXYSUCCINAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1993-08-18 | — | — | EP | disclosed |
| EP-0533913-A1 | NOVEL ENDOPEPTIDASE | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 1993-03-31 | — | — | EP | disclosed |
| WO-1992018516-A1 | NOVEL ENDOPEPTIDASE | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 1992-10-29 | — | — | WO | disclosed |
| US-5068354-A | Cathepsin B inhibitors, enzyme inhibitors for muscular disorders | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0407017-A1 | Epoxysuccinic acid derivatives useful as specific inhibitors of cathepsin B | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1991-01-09 | — | — | EP | disclosed |
| US-4474800-A | PROTEASE INHIBITORS, MUSCULAR DYSTROPHY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1984-10-02 | — | — | US | disclosed |
| US-4418075-A | INHIBITING CALCIUM ACTIVATED NEUTRALTHIOL PROTEASE, MUSCULAR DYSTROPHY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1983-11-29 | — | — | US | disclosed |
| JP-S55145678-A | PREPARATION OF EPOXYSUCCINYLLEUCYLAGMATINE | TAISHO PHARMACEUT CO LTD | 1980-11-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203073-A1 | SARS and Ebola inhibitors and use thereof, and methods for their discovery | CTSL, CTSV, CTSZ | CAPN1 253/4885CTSB 5/4885CTSL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.